Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012

Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Head injury patients develop brain clumps associated with Alzheimer's disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.

Pills for anxiety and sleep problems not linked to increased dementia risk
Taking benzodiazepines (widely used drugs to treat anxiety and insomnia) is not associated with an increased dementia risk in older adults, finds a study published by The BMJ today.

Fishing for answers about mercury consumption
It's a fishy situation: On the one hand, multiple scientific studies have found that eating seafood helps protect against dementia. On the other hand (or fin), seafood also is a source of the element mercury, which has been thought to cause damage to cells in the brain, contributing to cognitive impairment.

Study shows increased risk of early mortality in women with hypertensive disease
It has long been recognized that pregnancy puts considerable stress on the body and that there are specific conditions during pregnancy that will indicate lifelong health issues.

Study determines saliva gland test can spot early Parkinson's disease
Researchers from Mayo Clinic in Arizona and Banner Sun Health Research Institute have determined that testing a portion of a person's submandibular gland may be a way to diagnose early Parkinson's disease.

Gene study points towards therapies for common brain disorders
Scientists have pinpointed the cells that are likely to trigger common brain disorders, including Alzheimer's disease, Multiple Sclerosis and intellectual disabilities.

A key mechanism has been discovered which prevents memory loss in Alzheimer's disease
Neurons communicate with one another by synaptic connections, where information is exchanged from one neuron to its neighbor.

Chronic stress and anxiety can damage the brain
A scientific review paper warns that people need to find ways to reduce chronic stress and anxiety in their lives or they may be at increased risk for developing depression and even dementia.

Environmental toxin may increase risk of Alzheimer's disease and other neurodegenerative illnesses
A new study published today in the science journal Proceedings of the Royal Society B indicates that chronic exposure to an environmental toxin may increase risk of neurodegenerative illness.

Exercise for people with dementia improves balance and reduces dependence
Regular exercise improves balance for people with dementia and reduces dependence on assistance. This according to new research on healthcare for people suffering from dementia conducted at Umeå University in Sweden, which has now been published in the Journal of the American Geriatrics Society.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

Alzheimer 's Disease and Risks: Simplified

Alzheimer 's Disease and Risks: Simplified


This book is a comprehensive guide and review for anyone who wishes to learn about the Alzheimer’s disease. You may have someone in the family who suffers from it or you may just be curious to learn about it. Regardless, this book is sure to benefit you by providing you a complete interface of the disease. We will start from the very basics on what the disease actually is, how it starts and its scientific mechanism in comprehensive way.
In addition, the signs and symptoms will be talked about in detail in order to enable you to make an efficient diagnosis if you come across such an individual. We will also talk about who is more likely to be affected by it, how it can be treated, prevented and how to deal with it. This will be in terms of both the patient as well as the family....

Living With Alzheimer?s Disease: A Complete Guide to Caring for Someone with Alzheimer's

Living With Alzheimer?s Disease: A Complete Guide to Caring for Someone with Alzheimer's
by Linda H. Harris (Author)


Dementia, Memory Loss & Alzheimer’s Disease Alzheimer's Disease is a progressive form of dementia that kills brain cells, leading to continual loss of memory, intellectual capacity, and eventual death. Sadly, no treatment has been found to stop its progression. Living with Alzheimer's Disease: A Complete Guide to Caring for Someone with Alzheimer's provides a valuable resource for individuals struggling with the effects of Alzheimer's, and those who care for them. This book is filled with current information to help sufferers and their caretakers understand the many facets and stages of the disease. It explains initial signs that there may be a problem, diagnosis, the different stages, symptoms and suggestions for coping with them, and varied treatment plans, including helpful diet...

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk
by M.D. Kenneth S. Kosik (Author)


An easy-to-follow, research-based guide to the simple, low-cost choices that give the reader the power to reduce the risk of developing Alzheimer's disease and dementia; slow the progression of the disease; and mitigate symptoms and improve well-being.

Did you know that getting on the treadmill can help keep your brain sharp? Or that repeatedly staying up to catch the late show could increase the likelihood of being struck down by dementia? The dozens of choices you make over the course of any average day—ordering the curry versus the burger with fries, taking the stairs versus the elevator—all add up. Together with your family history, they establish your chances of getting Alzheimer’s years from now. No drugs or procedures can cure or even effectively treat Alzheimer’s...

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones
by Mary T Newport (Author)


In this second edition Dr. Newport, a neonatal practitioner, continues the story of Steve's progress and provides the most recent research on such topics as possible causes of Alzheimer's due to the herpes simplex virus and nitrosamine substances and how infection, inflammation and genetic makeup may affect an individual's response to fatty acid therapy.

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)


Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T Newport (Author)


Though Dr. Mary T. Newport has provided professional care to newborns since 1983, she's led a double life since 2000 when she became a caregiver at home. That's when her beloved husband, Steve, first showed signs of Alzheimer's disease. After his deterioration accelerated in 2004, Dr. Newport began avidly researching ways to keep him functional for as long as possible. Since she understands medical terminology and scientific methods, she was thrilled to find new research showing that medium- chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease. When she gave Steve about 2 tablespoons of coconut oil (a source of these fats) at breakfast before a memory test that he had previously failed,...

The Alzheimer's Prevention & Treatment Diet

The Alzheimer's Prevention & Treatment Diet
by Richard S. Isaacson MD (Author), Christopher N. Ochner PhD (Author)


Alzheimer’s disease (AD) is a type of dementia that can be very hard on both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer’s disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer’s disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer’s Prevention & Treatment Diet outlines a cutting-edge nutritional...

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease
by Dr. Benjamin T. Mast (Author), Scotty Smith (Foreword)


Charles is 78 years old and there is much he cannot remember. He cannot remember the names of his children, why he lives in a nursing home, or even whether he ate breakfast today. His forgetting causes confusion, and in his fear and uncertainty he sometimes lashes out at those who try to care for him. But when someone reads a favorite Psalm he quickly joins in, reciting each cherished word. When he hears an old hymn of faith, his hand slowly raises and he breathes out each word quietly, his face reflecting a peace that passes all understanding. Alzheimer’s disease has been described as the “defining disease” of the baby boomer generation. Millions of Americans will spend much of their retirement years either caring for a loved one with Alzheimer’s disease or experiencing its...

Counseling People with Early-Stage Alzheimer's Disease

Counseling People with Early-Stage Alzheimer's Disease
by Robyn Yale L.C.S.W. (Author)


People with early dementia face enormous challenges in coping with their condition, yet they typically receive no personalized education or support following the diagnosis. Counseling empowers them to understand and come to terms with the illness while also learning to manage and make healthy adaptations to it. With the rapid increase in people diagnosed with early memory impairment and demand for better support services this groundbreaking new guide gives you essential tools to become an integral partner in a process that helps people adjust to the many changes in their lives.

Presenting an innovative new counseling framework designed around the unique problems and needs arising from dementia, Counseling People with Early-Stage Alzheimer s Disease guides the counselor and client...

© 2016 BrightSurf.com